Re: Risk/benefit assessment of tamoxifen to prevent breast cancer - Still a work in progress? [1] (multiple letters)

Journal of the National Cancer Institute

Volumn 92, Issue 7, 2000, Pages 574-575

  Gail, Mitchell H ^a,f   Costantino, Joseph P ^b   Bryant, John ^b   Croyle, Robert ^a   Freedman, Laurence ^c   Helzlsouer, Kathy ^d   Vogel, Victor ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c BAR ILAN UNIVERSITY   (Israel)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CANCER STATISTICS; ETHNOLOGY; FEMALE; HUMAN; LETTER; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

AFRICAN AMERICANS; ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; INCIDENCE; RISK; RISK ASSESSMENT; TAMOXIFEN; UNITED STATES;

EID: 0034607240     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (0)